AstraZeneca has received approval from the European Commission for its tablet formulation of Calquence (acalabrutinib), which is used to treat adult patients with chronic lymphocytic leukaemia (CLL). This approval was based on positive results from the ELEVATE-PLUS trials, which showed that the tablet and capsule formulations of Calquence are bioequivalent in terms of efficacy and safety. The tablet can be taken with gastric acid-reducing agents, making it a more convenient treatment option for CLL patients who require daily medication for other conditions. According to Paolo Ghia, MD, the tablet formulation of Calquence will allow more patients with CLL to benefit from this medicine. AstraZeneca's Executive Vice President, Dave Fredrickson, emphasized the company's commitment to providing patient-oriented treatment solutions. Calquence is approved as a capsule formulation for CLL in the EU and as a capsule and tablet formulation for CLL, small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma (MCL) in the US and other countries worldwide. Indications may vary by market.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!